天津发展(00882)：力生制药中期归母净利润净利润3.43亿元 同比增加235.04%

Group 1 - The company Tianjin Development (00882) reported its indirect non-wholly-owned subsidiary Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical) financial results for the six months ending June 30, 2025, with total revenue of 732 million RMB, a year-on-year decrease of 1.76% [1] - The net profit attributable to the parent company was 343 million RMB, representing a significant year-on-year increase of 235.04% [1] - The basic earnings per share were reported at 1.33 RMB [1]